100s of titles, one news app for just $10 a month.
Dive Deeper:
MJ Harvest Signs Letter Of Intent To Merge With Cannabis Sativa, Inc.
MJ Harvest, Inc. (OTCQB: MJHI) signed a letter of intent to merge with Cannabis Sativa, Inc. (OTCPK: CBDS) The LOI provides for…
EXCLUSIVE: NASDAQ-Listed Enveric To Split Into Two Companies, One For Cannabinoids, One For Psychedelics
Enveric Biosciences (NASDAQ: ENVB), a biotech company working with cannabinoids and psychedelics, announced it will spin off its cannabinoid pipeline…
HEXO To File Management Information Circular, Recommends Shareholders Vote For The Resolutions
HEXO Corp.
Chicago Atlantic Reports Net Income Of $7.8M For Q1 2022, Higher Dividends
Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) released its results for the first quarter ended March 31, 2022.
One subscription that gives you access to news from hundreds of sites
22nd Century Group Acquires Privately-Held Cannabis & Hemp Co., Here's What's Next
22nd Century Group, Inc. (NASDAQ: XXII) announced the acquisition of privately held GVB Biopharma. GVB - a contract development and…
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours:
Get all your news in one place
Latest Technology news:
ICE ally Trust Stamp just fixed a massive security flaw
Names and driver’s license information for a few dozen people have been wrongly released.
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
Leno Tells Ford CEO He's A "Truck Guy" After Driving F-150 Lightning
Watch an interesting discussion between Jay Leno and Ford CEO Jim Farley as the famous car collector is introduced to…
Activision workers win vote to form industry's first big union in U.S.
The vote passed 19-3.
Snap Stock Plunges After Warning It Will Miss Second-Quarter Estimates
Snap stock plunged late Monday after saying the macroeconomic environment has deteriorated further and faster than anticipated.
How a genetically-engineered tomato could help solve a global health crisis
In this edition of HORIZONS, read about a genetically-engineered tomato rich in vitamin D, why air-filled tires may become a…
From analysis to good news, read the world’s best news in one place
Tesla Model Y Performance Owner Lists 10 Things He Hates About It
The Model Y Performance is a great electric vehicle, but it could become even better with several improvements, most of…
Porsche Taycan GTS Hockenheimring Edition Celebrates Track’s 90th Anniversary
This Taycan special edition features an appearance pack that adds decorative stitching, anniversary badges, bronze trim and a unique exterior…

Skye Bioscience Signs Arrangement Agreement With Emerald Health Therapeutics, Here Are The Details

By Vuk Zdinjak

Skye Bioscience, Inc. (OTCQB:SKYE) and Emerald Health Therapeutics, Inc. (OTCQB:EMHTF) (CSE:EMH) have entered into a definitive agreement with respect to a transaction to be completed by way of a plan of arrangement whereby Skye would acquire all of the issued and outstanding shares of Emerald in a share-for-share-transaction.

Skye is a San Diego-based pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet needs. Emerald possesses cash and non-cash assets that Skye would acquire through the arrangement. The proposed arrangement is subject to approval by each company’s common stockholders and by the Supreme Court of British Columbia, Canada.

As a result of the arrangement, current Skye stockholders would own approximately 54% of the common stock of Skye and former shareholders of Emerald would own approximately 46% of Skye’s common stock.

Skye possesses patented technology and know-how focused on enabling, enhancing and clinically validating therapeutic outcomes of uniquely modified and synthetically manufactured cannabinoid-derivative molecules. This outcome has already been shown in preclinical studies that have demonstrated notable advantages of Skye’s lead therapeutic drug, SBI-100 Ophthalmic Emulsion, over the established clinical standard of care for treating glaucoma and potentially represents a new and necessary class of therapeutic for the world’s leading cause of irreversible blindness. Through the completion of this transaction, Skye expects to have funding for a Phase 2 study it is planning to start in the fourth quarter of 2022, following a Phase 1 study beginning in the second quarter of 2022.

Details Of The Proposed Arrangement

Under the arrangement, Skye will issue Emerald shareholders 1.95 shares of Skye’s common stock in exchange for each Emerald share. Based on the number of outstanding shares as of the date of this press release, it is expected that Skye would issue approximately 416M Skye shares to Emerald shareholders. All stock options and warrants of Emerald will be exchanged for replacement options and warrants of Skye on identical terms, as adjusted in accordance with the exchange ratio.

The boards of directors of Emerald and Skye have unanimously approved the arrangement and recommend that their respective shareholders vote in favor of the arrangement.

Evans & Evans, Inc. provided an opinion to the board of directors of Emerald stating that as of the date of the opinion and based upon and subject to the assumptions, limitations, and qualifications set forth therein, the exchange ratio to be received by the holders of Emerald common shares pursuant to the arrangement is fair from a financial point of view to such holders.

The completion of the arrangement is subject to customary terms and conditions, including the following:

  • Approval of the arrangement by special resolutions of disinterested Skye and Emerald shareholders;

  • Court approval of the arrangement;

  • Receipt of all required regulatory approvals, including acceptance by the Canadian Securities Exchange of Skye’s listing on the CSE.

The arrangement is anticipated to close in the third quarter of 2022. Skye expects to file a proxy statement and supporting materials on Schedule 14A and will hold a special meeting of stockholders to seek approval of the arrangement and related stockholder proposals. Emerald expects to file an information circular required for Emerald’s shareholder meeting to seek approval of the arrangement.

Upon completion of the transaction, the combined company would continue to operate under the name Skye Bioscience, Inc. with its existing management team. Sukhwinder (Bobby) Rai, BSc. Biochem, BSc. Pharm, RPh., from Emerald’s board of directors would join Skye’s board of directors.

Photo: Courtesy of Skye Bioscience, Inc.

Related News

Skye Bioscience Shares Up On Keeping Novotech As CRO For Phase 1 Trial Of THC Prodrug Candidate For Glaucoma

HYTN Innovations To Accept Cannabis Orders Directly From Provinces & Territories

HYTN Innovations Receives Health Canada's Approval To Sell Cannabis

What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.

Dive Deeper:
MJ Harvest Signs Letter Of Intent To Merge With Cannabis Sativa, Inc.
MJ Harvest, Inc. (OTCQB: MJHI) signed a letter of intent to merge with Cannabis Sativa, Inc. (OTCPK: CBDS) The LOI provides for…
EXCLUSIVE: NASDAQ-Listed Enveric To Split Into Two Companies, One For Cannabinoids, One For Psychedelics
Enveric Biosciences (NASDAQ: ENVB), a biotech company working with cannabinoids and psychedelics, announced it will spin off its cannabinoid pipeline…
HEXO To File Management Information Circular, Recommends Shareholders Vote For The Resolutions
HEXO Corp.
Chicago Atlantic Reports Net Income Of $7.8M For Q1 2022, Higher Dividends
Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) released its results for the first quarter ended March 31, 2022.
One subscription that gives you access to news from hundreds of sites
22nd Century Group Acquires Privately-Held Cannabis & Hemp Co., Here's What's Next
22nd Century Group, Inc. (NASDAQ: XXII) announced the acquisition of privately held GVB Biopharma. GVB - a contract development and…
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours:
Get all your news in one place